Evonik’s Strong Growth Potential and Resilience: A Buy Recommendation by Andreas Heine

Stifel Nicolaus analyst Andreas Heine has maintained their bullish stance on 0QDS stock, giving a Buy rating on March 6.

Andreas Heine has given his Buy rating due to a combination of factors that highlight Evonik’s strong position and growth potential. The company’s CEO expressed confidence in achieving the FY-25 guidance, with a projected EBITDA increase of approximately 5% year-over-year. This growth is supported by significant cost savings and reduced energy costs, which are expected to bring the company to the mid-point of its guidance.
Evonik’s resilience to US tariffs, with a substantial portion of its sales coming from local production, positions it well against potential market disruptions. Additionally, the company benefits from high tariffs on Chinese methionine imports to the US. The sustainable capex budget and a focus on paying down debt further strengthen Evonik’s financial position. Furthermore, the company’s innovation growth areas have met their targets, with plans to expand sales significantly by 2032, indicating a robust strategy for future growth.

In another report released on March 6, Deutsche Bank also maintained a Buy rating on the stock with a €24.00 price target.

0QDS’s price has also changed slightly for the past six months – from EUR20.522 to EUR22.256, which is a 8.45% increase.